These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19349485)

  • 1. Prognosis and reevaluation of lung cancer by positron emission tomography imaging.
    Erasmus JJ; Rohren E; Swisher SG
    Proc Am Thorac Soc; 2009 Apr; 6(2):171-9. PubMed ID: 19349485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
    Truong MT; Viswanathan C; Erasmus JJ
    J Thorac Imaging; 2011 May; 26(2):132-46. PubMed ID: 21508735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of FDG PET in the management of NSCLC.
    Ukena D; Hellwig D
    Lung Cancer; 2004 Aug; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography imaging in nonsmall-cell lung cancer.
    Erasmus JJ; Macapinlac HA; Swisher SG
    Cancer; 2007 Nov; 110(10):2155-68. PubMed ID: 17896784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18-Fluorodeoxyglucose positron emission tomography (FDG-PET) and the staging of early lung cancer.
    Laking G; Price P
    Thorax; 2001 Sep; 56 Suppl 2(Suppl 2):ii38-44. PubMed ID: 11514705
    [No Abstract]   [Full Text] [Related]  

  • 6. FDG PET: advantages for staging the mediastinum?
    Franzius C
    Lung Cancer; 2004 Aug; 45 Suppl 2():S69-74. PubMed ID: 15552784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography on therapeutic management of non-small cell lung cancer.
    Heo EY; Yang SC; Yoo CG; Han SK; Shim YS; Kim YW
    Respirology; 2010 Nov; 15(8):1174-8. PubMed ID: 20573060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron Emission Tomography (PET) radiotracers in oncology--utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC).
    Miele E; Spinelli GP; Tomao F; Zullo A; De Marinis F; Pasciuti G; Rossi L; Zoratto F; Tomao S
    J Exp Clin Cancer Res; 2008 Oct; 27(1):52. PubMed ID: 18928537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
    Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
    Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET in lung cancer staging.
    Coleman RE
    Q J Nucl Med; 2001 Sep; 45(3):231-4. PubMed ID: 11788815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of FDG-PET in the management of non-small cell lung carcinoma.
    Ho Shon IA; Maisey MN
    Ann Acad Med Singap; 2004 Mar; 33(2):166-74. PubMed ID: 15098629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer.
    Patz EF; Connolly J; Herndon J
    AJR Am J Roentgenol; 2000 Mar; 174(3):769-74. PubMed ID: 10701623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of FDG-PET scanning in stage IIIAN2 non-small cell lung cancer].
    Colavolpe C; Bonardel G; Guedj E; Cammilleri S; Mundler O; Barlesi F
    Rev Mal Respir; 2012 Feb; 29(2):149-60. PubMed ID: 22405110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET imaging in the management of non-small-cell lung cancer.
    Salminen E; Mac Manus M
    Ann Oncol; 2002 Mar; 13(3):357-60. PubMed ID: 11996464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.
    Hicks RJ
    J Nucl Med; 2009 May; 50 Suppl 1():31S-42S. PubMed ID: 19380411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Present and future roles of FDG-PET/CT imaging in the management of lung cancer.
    Kitajima K; Doi H; Kanda T; Yamane T; Tsujikawa T; Kaida H; Tamaki Y; Kuribayashi K
    Jpn J Radiol; 2016 Jun; 34(6):387-99. PubMed ID: 27121156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT--a prospective study.
    Kim BT; Lee KS; Shim SS; Choi JY; Kwon OJ; Kim H; Shim YM; Kim J; Kim S
    Radiology; 2006 Nov; 241(2):501-9. PubMed ID: 16966480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [18F]Fluorodeoxyglucose PET in Thoracic Malignancies.
    Vilstrup MH; Torigian DA
    PET Clin; 2014 Oct; 9(4):391-420, v. PubMed ID: 26050944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.